Clinical trial · no report yet · Phase 3
NCT05173987
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
- NCT05173987 ↗
- Active not recruiting
- Merck Sharp & Dohme LLC
- 37 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 19 | |
| Podcasts | 17 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Endometrial Neoplasms
- Interventions
- pembrolizumab; carboplatin; paclitaxel; docetaxel; cisplatin
- Arms
- Pembrolizumab · Experimental
- Carboplatin+paclitaxel · Active comparator
- Enrollment
- 280 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Overall Survival
- Sponsor
- Merck Sharp & Dohme LLC with European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
- Start
- Feb 3, 2022
- Primary completion
- May 27, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05173987 · updated May 5, 2026
Publications
linked from the registry- Secord AA, Powell MA, McAlpine J. Molecular Characterization and Clinical Implications of Endometrial Cancer. Obstet Gynecol. 2025 Nov 1;146(5):660-671. doi: 10.1097/AOG.0000000000006080. Epub 2025 Sep 18. PubMed 40966692